Pancreatic cancer survival analysis with SEER and active follow-up in SF Bay Area

描述（由申请人提供）：在旧金山湾区进行SEER和积极随访的胰腺癌生存分析，在美国每年诊断出约30,000例胰腺癌（PC），其死亡人数几乎相等。生存是令人沮丧的；75%的患者在一年内死亡，小于4%的患者存活超过或等于5年。目前还没有发表的研究确定环境因素（非临床）与基于人群的PC患者生存之间的关系，也没有基于人群的研究对包括一系列不同人群在内的特定SEER区域的所有PC患者进行完整和积极的随访。通过主动监测，我们将确定1995年至1999年诊断的近2000名PC患者的准确的基于人群的相对生存率，这些患者是通过北加州SEER登记处确定的，该登记处是旧金山湾区6个县基于人群的PC病例对照研究的一部分。我们将：1；使用SEER摘要和主动监测报告的临床和人口统计数据，比较访谈和非访谈PC患者的相对生存率；2. 确定和描述在主要研究中面对面访谈中收集的与生存和相关的风险因素数据；3. 通过我们对患者生命状态的积极随访，对长期幸存者进行描述性分析。应用程序的优点是：1。根据SEER摘要对所有存活或失去随访的患者进行随访，以获得当前和完整的生命统计数据，使我们能够计算出比单独基于SEER摘要生命状态数据更准确的相对存活率；2. 使用流行病学暴露数据和SEER数据对受访患者进行生存分析的能力；3. 描述受访患者生存与某些遗传和分子因素之间关系的能力；4. 收集长期PC幸存者的随访病理、临床和流行病学数据的能力；5. 像这样彻底的生存分析从未对PC进行过。我们的结果将提供与PC患者生存期相关或预测生存期的新的、独特的暴露和条件数据。这些知识可以转化为筛查和预防策略以及假设生成。这项工作也将成为幸存者登记的基础，以收集临床、病理、流行病学和家族史数据，目前无法用于PC。

DESCRIPTION (provided by applicant): Pancreatic cancer survival analysis with SEER and active follow-up in SF Bay Area Each year >30,000 incident cases of pancreatic cancer (PC) are diagnosed in the U.S. with nearly an equivalent number of PC deaths. Survival is dismal; 75% of patients die within one year and <4% survive greater than or equal to 5 years. No studies have been published that determine the relationship between environmental factors (non-clinical) and survival in population-based PC patients, nor have population-based studies conducted complete and active follow-up of all PC patients in a defined SEER area that includes a range of diverse populations. Using active surveillance beyond that done by SEER, we will determine an accurate population-based relative survival rate for nearly 2000 PC patients diagnosed from 1995 to 1999 who were identified through the Northern California SEER registry as part of a large population-based case-control study of PC in 6 San Francisco Bay Area counties. We will: 1. using clinical and demographic data reported on SEER abstracts and active surveillance, compare relative survival rates between interviewed and non-interviewed PC patients; 2. determine and describe risk factor data collected during in-person interviews in the main study that are associated with survival and; 3. conduct a descriptive analysis of long-term survivors identified through our active follow-up of patient vital status. The application strengths are: 1. follow-up of all patients who are alive or lost to follow-up per SEER abstract to obtain current and complete vital statistics that will allow us to compute a relative survival rate that is more accurate than that based on SEER abstract vital status data alone; 2. the ability to conduct survival analyses in interviewed patients using epidemiologic exposure data and SEER data; 3. the ability to describe the association between survival and some genetic and molecular factors in interviewed patients; 4. the ability to collect follow-up pathological, clinical and epidemiologic data from long-term PC survivors and; 5. thorough survival analyses such as these never have been conducted for PC. Our results will provide new, unique data about exposures and conditions that are associated with or predictive of survival duration in PC patients. This knowledge may be translated to screening and prevention strategies and for hypothesis generation. This work also will be a foundation for a survivorship registry to collect clinical, pathological, epidemiological and family history data that currently is unavailable for PC.